Alumni Ventures Group, LLC is a venture capital firm based in Manchester, New Hampshire, founded in 2013. The firm specializes in seed and early-stage investments, as well as late-stage pre-IPO opportunities, with a flexible approach that is sector and geographic agnostic. Alumni Ventures aims to provide high-quality, diversified venture portfolios to individual investors, particularly accredited alumni from top entrepreneurial schools, who may not have had access to venture capital previously. The firm focuses on backing companies that have an alumni connection and are led by established institutional investors with expertise in their respective fields. Additionally, Alumni Ventures offers focused funds that enable accredited investors to access a diverse portfolio of investments across various types, sectors, stages, and geographies.
Managing Partner, Castor Ventures and Strawberry Creek Ventures
Brittney Wade
Senior Associate, Seed Fund and Doctors Innovate Fund
Drew Wandzilak
Senior Associate, Green D and Yard and Strategic Tech Fund
Sarah Worden
Venture Scout
Ray Wu
Managing Partner-Web3 / Blockchain Fund
Michael Yuann
Director of Investment Operations
Ron Levin
Managing Partner, AV Seed Fund and Doctors Innovate Fund
Past deals in Medical
Canid
Series A in 2024
Candid simplifies pediatricians’ work by redesigning how the vaccination process works. The company's scanning system eliminates the need for manual data entry and uploads vaccine information into state registries.
InGel Therapeutics
Seed Round in 2024
InGel Therapeutics is a platform technology company that develops stem cell therapeutics and biodegradable polymers. The company was founded in 2021 and is based in Cambridge, Massachusetts.
Grayce
Series A in 2024
Grayce, Inc. is a health care agency based in San Francisco that specializes in providing personalized support for families and employees managing the care of aging adults and children. Established in 2019, Grayce offers a comprehensive range of services, including assistance with insurance, finances, legal plans, medical care, home care, housing, and daily needs. The company emphasizes individualized guidance, ensuring that each member receives dedicated support from a social worker who helps manage their overall care. This includes planning, resource identification, care coordination, and advocacy, empowering family caregivers to effectively navigate the complexities of caring for their loved ones.
Nectero Medical
Series D in 2024
Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, that focuses on treating mid-sized abdominal aortic aneurysms. Founded in 2017, the company has developed an innovative treatment designed to stabilize the growth of aneurysms and prevent their rupture. This treatment delivers a compound containing a stabilizer agent directly to the aneurysm site, which helps inhibit further breakdown and strengthens the vessel wall. By providing a safer intervention option, Nectero Medical aims to enable patients to receive timely care, significantly delaying or preventing the need for major endovascular or surgical repair.
Nest Health
Seed Round in 2024
Nest Health is a family healthcare platform that provides a range of medical services aimed at reducing the stress associated with traditional healthcare arrangements. The company specializes in delivering in-home and virtual visits for patients of all ages, including newborns, children, teens, and adults. Their offerings encompass preventive care, sick visits, behavioral health support, nutrition guidance, and chronic disease management. By enabling patients to receive care in the comfort of their homes, Nest Health seeks to enhance accessibility and convenience in healthcare delivery.
Cyrus Biotechnology
Series B in 2024
Cyrus Biotechnology, Inc. specializes in developing software tools for protein structure prediction and design, aiming to enhance research in biotechnology and pharmaceuticals. The company's flagship product, Rosetta, allows for the design of biologically active proteins that can address critical health issues, such as brain cancer treatment and gluten breakdown in Celiac Disease patients. Additionally, Cyrus Bench offers an enterprise version of the Rosetta toolkit, equipped with a variety of bio-molecular computation tools. The company also provides Cyrus CryoEM services, which include advanced structure refinement and model building. Founded in 2014 and headquartered in Seattle, Washington, Cyrus Biotechnology serves a diverse clientele, including pharmaceutical companies, venture-backed startups, and mid-sized biotech firms focused on therapeutic discovery and industrial biotechnology innovation.
Pendulum Therapeutics
Series C in 2024
Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.
Oula Health
Series B in 2024
Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.
Granata Bio
Series A in 2024
Granata Bio is a biotechnology company established in 2018, dedicated to identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility treatments and possesses expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in the field of fertility treatment. Recently, the company announced a collaboration with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to advancing fertility care.
Piction Health
Seed Round in 2024
Piction Health is a dermatology care service that provides patients with rapid access to expert dermatological consultations for skin, hair, or nail concerns. Through its application, the company facilitates a streamlined process where patients receive a diagnosis and personalized care plan within two days. Piction Health employs artificial intelligence to enhance the experience for both patients and healthcare providers, enabling primary care physicians to obtain quick second opinions on complex skin conditions. This approach not only improves patient outcomes but also reduces unnecessary repeat visits and ineffective treatments, ultimately accelerating access to high-quality dermatology care from the comfort of home.
DocStation
Seed Round in 2023
DocStation, Inc. is a cloud-based patient care platform designed for pharmacists, incorporated in 2017 and headquartered in Austin, Texas. The platform connects payers and pharmacists to facilitate value-based programs, aiming to reduce healthcare costs while enhancing patient outcomes. With over 500 providers collaborating with innovative health plans, DocStation equips pharmacists with tools that streamline patient management. Its comprehensive dashboard allows for the maintenance of current diagnoses, medications, immunizations, and allergies, while also facilitating the creation of care plans, monitoring adherence, and scheduling follow-ups. By enabling real-time connections between pharmacists and patients, DocStation supports a shift towards value-based care in the pharmacy sector.
CytoVale
Series C in 2023
CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.
Canid
Seed Round in 2023
Candid simplifies pediatricians’ work by redesigning how the vaccination process works. The company's scanning system eliminates the need for manual data entry and uploads vaccine information into state registries.
PulzAid
Pre Seed Round in 2023
PulzAid operates a managed marketplace focused on assisting injured workers in accessing a range of healthcare services, including telehealth, mobile imaging, and specialist consultations. By leveraging purpose-built software and established relationships with orthopedic surgeons and occupational medicine doctors, PulzAid aims to expedite treatment for employees, fostering quicker recovery and return to work. The company promotes a preventative approach to workplace injuries, offering services like on-demand video visits, in-person nurse visits, lab testing, and prescription services. This comprehensive model not only helps improve employee health outcomes but also assists employers in reducing costs associated with workplace injuries and workers' compensation claims.
Dentologie
Venture Round in 2023
Dentologie, founded by Dr. Hany Kurdi in 2013 and headquartered in Chicago, Illinois, aims to transform the dental experience by creating safe and inclusive environments for patients. The company specializes in urban dental solutions, providing a range of tech-enabled services that include general dentistry, Invisalign treatment, oral surgery, and cosmetic dentistry. Dentologie is committed to exceptional customer service and thoughtful design, ensuring that each patient receives personalized care and convenient access to dental solutions. By prioritizing compassion and competence, Dentologie seeks to change the perception of dental visits and enhance overall oral health.
Ossium Health
Series C in 2023
Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.
Upside Health
Seed Round in 2023
Upside Health, Inc. is a healthcare technology company based in New York, founded in 2017, that focuses on chronic pain management through its mobile application, Ouchie. This application provides targeted educational content and rewards for achieving functional milestones, fostering a support system for patients. Upside Health's platform includes remote patient monitoring and engagement tools that enable clinicians to enhance care quality while minimizing the burden on healthcare providers. By empowering patients with data and social support, Upside Health aims to improve outcomes for chronic pain sufferers and create revenue-generating opportunities for healthcare practices.
PharmaCCX
Seed Round in 2023
PharmaCCX, Inc. is a company that operates a market access platform designed to streamline the pricing and procurement of medicines for healthcare payers, thereby facilitating quicker patient access to necessary treatments. The platform primarily supports oncology pharmaceutical companies and various healthcare systems in the United States and Europe. Founded in 2017 and headquartered in Boston, Massachusetts, PharmaCCX also maintains offices in Stockholm, Sweden; San Mateo, California; and Zug, Switzerland. The company's software enhances the efficiency of market access teams within pharmaceutical companies and payers, enabling them to effectively plan, negotiate, and manage innovative payment models.
Mend
Series A in 2023
MEND is a life sciences company dedicated to advancing health and recovery through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that enhance patient outcomes in various contexts, including injury recovery, surgical recovery, aging, and physical performance. MEND's solutions have been widely adopted by hospitals, health systems, and professional sports teams across major leagues, as well as by the elite forces of the US Military. Through its commitment to ongoing research and development, MEND aims to empower caregivers and improve health outcomes for individuals facing diverse health challenges.
Pharmacy Mart
Seed Round in 2023
Pharmacy Mart is an online business-to-business marketplace established in 2021 and based in Cairo, Egypt. The platform facilitates pharmacists in obtaining daily prescriptions and medications from various suppliers, allowing them to access a wide range of pharmacy supplies efficiently. By integrating fintech and logistics, Pharmacy Mart provides a user-friendly interface where medical suppliers can list their products, enabling pharmacists to find suitable offers for their daily supply needs. The service also includes discounts and eliminates delivery charges, making it a cost-effective solution for pharmacy operations.
DropStat
Venture Round in 2023
DropStat is an app-based software that eliminates the call, text, and wait process of calling staff into open shifts. It also helps hospitals optimize their labor costs by reducing financial waste and improving the patient and staff experience. The company's vision is to bring communication into the 21st century with AI and machine learning, voice technology, and a full suite of tools to eliminate financial waste, increase speed and efficiency, and upgrade staff and patient satisfaction.
Pathfinder Health
Seed Round in 2023
Pathfinder Health is focused on enhancing child development for children aged 0-5 through its evidence-based clinical tool. This pediatric application aids parents and caregivers in monitoring developmental milestones, encouraging cognitive, physical, social, emotional, and communication growth through play. It facilitates communication with healthcare providers, allowing for earlier diagnoses of potential developmental issues. The app offers step-by-step guidance tailored to a child's current stage of development and connects users to additional resources, including developmental activities, articles, parenting tips, and local early intervention services. By providing these tools, Pathfinder Health empowers families to track their child's progress and seek timely intervention when necessary.
Bionic Health
Seed Round in 2023
Bionic Health is a digital healthcare company focused on providing preventative health services, particularly for individuals experiencing chronic pain. The company has developed a platform that utilizes frequent diagnostics and machine learning to create personalized treatment plans. This approach emphasizes slowing down the aging process and offers patients tailored insights derived from ongoing assessments. By implementing an iterative journey, Bionic Health enables users to identify their unique health needs and make impactful lifestyle changes over time. Additionally, patients benefit from closely monitored preventative care throughout the year, enhancing their overall well-being.
Dimension Inx
Series A in 2023
Dimension Inx Corp. focuses on designing and developing three-dimensional (3D) printable materials and painted objects for research and commercial applications. The company specializes in creating regenerative microenvironments that aid the body in self-healing. Its biomaterials platform incorporates a complex interplay of material composition, microstructure, and microarchitecture to enhance biofunctionality. Dimension Inx offers a range of products, including Hyperelastic Bone for bone regeneration, 3D printable elastomers, bioactive ceramics, and solutions for soft tissue regeneration. Founded in 2016 and based in Chicago, Illinois, the company aims to provide innovative therapeutic products that restore tissue and organ function, potentially reducing the need for organ transplantation through advanced bio-fabrication processes.
Precision Neuroscience
Series B in 2023
Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.
Oula Health
Series A in 2023
Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.
Gilgamesh Pharmaceuticals
Series B in 2022
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.
Axoft
Seed Round in 2022
Axoft offers a bioinspired, scalable implant that promotes long-term communication with the nervous system, transforming clinical outcomes, individual health, and the human experience.
SURGE Therapeutics
Series A in 2022
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.
Brave Health
Series C in 2022
Brave Health operates a virtual clinic that provides telehealth services focused on mental health and addiction treatment. Established in 2017 in Miami, Florida, the company specializes in behavioral health, offering a range of services including counseling, therapy, psychiatry, and medication management, which encompasses medication-assisted treatment. This telehealth approach allows patients to receive comprehensive care for various conditions related to mental health and substance use disorders, facilitating greater access to necessary treatment.
Koala Health
Series A in 2022
Koala Health is a Boston-based company founded in 2021 that specializes in providing medications and health products for pets. The company simplifies pet care by verifying and fetching prescriptions from veterinarians, sorting and packaging medications by date and time, and offering free delivery and refills. By focusing on vet-approved medications and supplements, Koala Health aims to enhance the quality of life for pets and support pet owners in managing their pets' health needs effectively.
Remedial Health
Seed Round in 2022
Remedial Health operates as a wholesale distributor of medicine, catering to the vast network of approximately one million pharmacies and hospitals across Africa. The company addresses the prevalent inefficiencies in the healthcare supply chain, where providers often depend on open-air markets to acquire pharmaceuticals, leading to risks of counterfeit products. By offering a pharmacy operations and procurement management platform, Remedial Health enhances business-to-business access to medications. This platform incorporates technology that simplifies the ordering process and facilitates direct access to retail medicines from manufacturers or distributors, thereby improving workflow management and ensuring a more reliable supply of genuine medications for healthcare providers.
Nanopath
Series A in 2022
Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.
Moving Analytics
Series A in 2022
Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years of research in remote disease management from Stanford University.
Swing Therapeutics
Series A in 2022
Swing is creating the next generation of safe and effective digital therapeutics for people with chronic conditions. Our team of passionate scientists, clinicians, and technologists are partnering with some of the world’s top researchers to develop evidence-based transformative digital treatments. Swing’s solutions empower patients to regain control of their illnesses. Together, we are helping people achieve improved health so that they can lead more joyful, vibrant lives.
Boulder Care
Series B in 2022
Boulder is a digital health platform expanding access to effective treatment for opiate use. We aim to move the behavioral health industry forward by offering dramatically better experiences for patients and their care teams.
Pharmacy Mart
Seed Round in 2022
Pharmacy Mart is an online business-to-business marketplace established in 2021 and based in Cairo, Egypt. The platform facilitates pharmacists in obtaining daily prescriptions and medications from various suppliers, allowing them to access a wide range of pharmacy supplies efficiently. By integrating fintech and logistics, Pharmacy Mart provides a user-friendly interface where medical suppliers can list their products, enabling pharmacists to find suitable offers for their daily supply needs. The service also includes discounts and eliminates delivery charges, making it a cost-effective solution for pharmacy operations.
NeuraLight
Series A in 2022
NeuraLight is a venture-backed company focused on improving the lives of individuals affected by neurological disorders through digital solutions. The company has developed a digital neurology platform that utilizes a proprietary, de-identified oculometric database. This technology allows for the analysis of eye movement using standard smartphones or webcams, enabling clinicians to effectively differentiate between patients and healthy individuals, categorize various subgroups, and track disease progression. By digitizing evaluation and care, NeuraLight aims to enhance diagnostic accuracy and treatment for those impacted by neurological conditions.
Legacy
Series B in 2022
Legacy provides a service for at-home sperm testing and cryopreservation, allowing individuals to take control of their fertility health from the comfort of their homes. Their semen analysis is conducted in CLIA-certified labs, ensuring high-quality testing without the need for direct doctor involvement. As America's largest at-home fertility clinic for men, Legacy empowers clients to understand their reproductive health and plan for the future effectively.
American Gene Technologies
Series D in 2022
American Gene Technologies (AGT) specializes in developing innovative gene therapies aimed at curing serious diseases, including infectious diseases, cancers, and inherited disorders. The company is advancing its proprietary gene-delivery platform, which is backed by multiple patents, including those for its AGT103-T cell product designed to functionally cure HIV. AGT is also focused on a unique immuno-oncology approach that stimulates gamma-delta T cells to target various solid tumors. Additionally, the company has developed a synthetic gene to provide effective treatments for Phenylketonuria (PKU). AGT’s clinical trial for an HIV cure has the potential to not only address a significant public health challenge but also validate its technology platform for treating a variety of diseases.
Satellite Bio
Series A in 2022
Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.
Curbside Health
Seed Round in 2022
Curbside Health develops clinical decision support software that aligns health systems and clinicians to more efficiently deliver optimal care. The company was founded by physicians and technologists to combine the best of clinical evidence with the realities of healthcare delivery and with opportunities of modern web technology. We support health systems and hospitals to expand their clinical content library (e.g. clinical pathways, protocols, guidelines, A3s, checklists, etc) and enhance the utilization of these resources at the point-of-care. Together, the components of Curbside's platform enable a hospital to improve clinical outcomes and operational efficiencies. Product development is informed by working closely with patients, clinicians, engineers, physicians, healthcare administrators, and payors. Our mission is hiding in plain sight within our name, and those in healthcare will understand: every medical decision is informed in real-time by the world's expert of that particular situation, while simultaneously accounting for hospital policy and all relevant patient-specific data. Essentially, Curbside is on a never-ending quest to perfect medical decision making.
Iterative Scopes
Series B in 2022
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.
Hey Jane
Seed Round in 2022
Hey Jane is a telehealth startup that connects patients to healthcare providers that offer online medical consultations. The company's innovative Complete Care model utilizes technology for unparalleled layers of support: medical, emotional, and social. Since 2021, Hey Jane has helped nearly 20,000 patients get the care they need. And this is only the beginning; soon, we will reimagine care for even more common but underserved treatments, with the ultimate goal of becoming the most trusted healthcare company out there—one that pushes the boundaries of access with convenient, inclusive, and patient-driven care.
Luma Health
Series C in 2021
Luma Health Inc. is a San Francisco-based company that specializes in developing a patient engagement platform aimed at enhancing the connection between healthcare providers and patients. Founded in 2015, the platform facilitates smart scheduling and referral management while offering features such as appointment reminders, mobile patient intake, and care pathways. It enables healthcare systems and clinics to keep their schedules full and supports patient adherence to care plans. Additionally, Luma Health provides tools for patient communication and analytics, ensuring that healthcare providers can deliver continuous care and improve treatment outcomes. The company emphasizes a modern, mobile-first approach to patient engagement.
Gordy Health
Convertible Note in 2021
Gordy Health is a virtual care provider specializing in blood pressure management to reduce the risk of serious health complications such as heart attacks, strokes, and kidney failure. Founded in 2021 and headquartered in Pasadena, California, the company offers a healthcare platform that allows users to manage their blood pressure from home. This platform provides direct access to heart specialists, facilitates easy scheduling of virtual appointments, and includes features such as real-time diagnostics, prescription delivery, and continuous monitoring and medication adjustments. By focusing on proactive management of high blood pressure, Gordy Health aims to help individuals lead healthier lives and extend their longevity.
Evernow
Convertible Note in 2021
Evernow is a provider of women's health care services focused on supporting women before, during, and after menopause. The company offers an online teleconsultation platform that connects users with specialized doctors and provides access to science-backed information and treatments. Through this platform, Evernow facilitates conversations about effective care for managing changing hormones, empowering women to lead longer and healthier lives.
GritWell
Seed Round in 2021
GritWell Ltd is a digital health platform established in 2018, based in San Francisco, California. The company focuses on addressing chronic health conditions by shifting the emphasis from symptom management to identifying and treating root causes. GritWell connects patients suffering from various chronic symptoms, such as insomnia, migraines, digestive issues, anxiety, and joint pain, with nutritionists, health coaches, and holistic practitioners. Its platform offers personalized care through clinically validated symptom assessments and facilitates secure video consultations, direct messaging, and an online portal for scheduling and managing patient records. By integrating natural treatments and providing tailored treatment plans, GritWell aims to enhance patient outcomes and support a holistic approach to health.
Cyrus Biotechnology
Venture Round in 2021
Cyrus Biotechnology, Inc. specializes in developing software tools for protein structure prediction and design, aiming to enhance research in biotechnology and pharmaceuticals. The company's flagship product, Rosetta, allows for the design of biologically active proteins that can address critical health issues, such as brain cancer treatment and gluten breakdown in Celiac Disease patients. Additionally, Cyrus Bench offers an enterprise version of the Rosetta toolkit, equipped with a variety of bio-molecular computation tools. The company also provides Cyrus CryoEM services, which include advanced structure refinement and model building. Founded in 2014 and headquartered in Seattle, Washington, Cyrus Biotechnology serves a diverse clientele, including pharmaceutical companies, venture-backed startups, and mid-sized biotech firms focused on therapeutic discovery and industrial biotechnology innovation.
SHINE Technologies
Series C in 2021
SHINE Technologies specializes in the production of medical isotopes and the development of fusion technology. Its proprietary processes create essential isotopes such as molybdenum-99 and non-carrier-added lutetium-177, which are vital for diagnosing and treating serious health conditions, including heart disease and various forms of cancer. SHINE serves multiple sectors, including healthcare, aerospace, defense, and energy, providing safe and environmentally friendly solutions for industrial inspections and medical applications. The company is also focused on advancing its fusion technology to address energy challenges, including the recycling of nuclear waste. Through a phased and purpose-driven approach, SHINE aims to generate clean, abundant fusion energy, contributing to a healthier and more sustainable future.
miRecule
Venture Round in 2021
miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.
Future Family
Series A in 2021
Future Family, Inc. is a subscription-based fertility company founded in 2016 and located in San Francisco, California. The company provides comprehensive fertility services, including personalized fertility planning, clinic matching, and access to a dedicated nurse concierge. Its offerings encompass on-demand medical support, guided care, and a digital health platform that facilitates clinic visits, procedures, laboratory tests, and medications. Additionally, Future Family offers customized financing plans for fertility procedures such as in vitro fertilization (IVF) and egg freezing, ensuring that individuals and couples can navigate their fertility journeys with financial assistance and expert support.
Gilgamesh Pharmaceuticals
Series A in 2021
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.
Intus Care
Seed Round in 2021
Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.
PulseData AI
Series A in 2021
PulseData operates a healthcare management platform that leverages machine learning to predict health outcomes, enabling healthcare providers to deliver targeted care to patients who need it most. By analyzing a vast array of individual and population health data, PulseData equips healthcare enterprises with adaptive and predictive tools to identify and mitigate health risks. This approach not only aims to enhance patient care but also seeks to achieve medical cost savings by preventing sickness. Care management teams utilize PulseData's capabilities to ensure that the right care reaches the right individuals at the appropriate time, ultimately improving overall healthcare efficiency.
KLOWEN Braces
Seed Round in 2021
KLOWEN Braces, Inc. is a company based in Fort Collins, Colorado, that specializes in developing custom braces systems for orthodontists and their patients. Founded in 2019, KLOWEN Braces utilizes a software platform to create ideally shaped brackets for each tooth, enhancing the effectiveness and comfort of the orthodontic treatment. The company offers a range of products, including prefabricated, modular brackets, as well as brackets with hooks, bundles, tubes, and wires, available for online purchase. By combining innovative technology with quality materials, KLOWEN aims to provide a faster and more comfortable alternative to traditional braces.
InteRNA Technologies
Series B in 2021
InteRNA Technologies B.V. is a biotechnology company focused on the development of microRNA (miRNA)-based therapeutics for cancer treatment. The company's innovative approach leverages the unique properties of miRNAs to target previously undruggable pathways involved in cancer initiation, progression, and metastasis. By utilizing advanced techniques such as massively parallel sequencing and proprietary bioinformatics, InteRNA analyzes and validates miRNA sequences to enhance drug efficacy and reduce resistance to existing therapies. Founded in 2006, the company operates from Nijmegen, the Netherlands, and has a dedicated research and development center in Utrecht. Recently, InteRNA has secured additional equity financing to advance its lead program for melanoma treatment, demonstrating its commitment to developing novel solutions in oncology.
Centivo
Series B in 2020
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.
STIMIT
Venture Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.
Shoulder Innovations
Venture Round in 2020
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.
SHINE Technologies
Venture Round in 2020
SHINE Technologies specializes in the production of medical isotopes and the development of fusion technology. Its proprietary processes create essential isotopes such as molybdenum-99 and non-carrier-added lutetium-177, which are vital for diagnosing and treating serious health conditions, including heart disease and various forms of cancer. SHINE serves multiple sectors, including healthcare, aerospace, defense, and energy, providing safe and environmentally friendly solutions for industrial inspections and medical applications. The company is also focused on advancing its fusion technology to address energy challenges, including the recycling of nuclear waste. Through a phased and purpose-driven approach, SHINE aims to generate clean, abundant fusion energy, contributing to a healthier and more sustainable future.
Conversa Health
Venture Round in 2020
Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.
Conversa Health
Series B in 2020
Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.
Better Life Partners
Series A in 2020
Better Life Partners Inc. is a healthcare provider based in Hanover, New Hampshire, focused on supporting individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners utilizes technology to create personalized care plans that adapt to clients' needs, ensuring effective healthcare delivery through telehealth and community-based solutions. By integrating medical and behavioral healthcare, the company aims to address the complex needs of patients, providing comprehensive support to help them recover from addiction. Better Life Partners has additional offices across various locations in New Hampshire, reflecting its commitment to serving vulnerable populations.
Grayce
Seed Round in 2020
Grayce, Inc. is a health care agency based in San Francisco that specializes in providing personalized support for families and employees managing the care of aging adults and children. Established in 2019, Grayce offers a comprehensive range of services, including assistance with insurance, finances, legal plans, medical care, home care, housing, and daily needs. The company emphasizes individualized guidance, ensuring that each member receives dedicated support from a social worker who helps manage their overall care. This includes planning, resource identification, care coordination, and advocacy, empowering family caregivers to effectively navigate the complexities of caring for their loved ones.
Mission Bio
Venture Round in 2020
Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Emulate
Series D in 2020
Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.
Emulate
Debt Financing in 2020
Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.
Matchwell
Venture Round in 2020
Matchwell LLC is an online marketplace that connects healthcare professionals, such as nurses and therapists, with healthcare facilities seeking staff. Founded in 2017 and headquartered in Durham, North Carolina, Matchwell allows clinicians to join preferred facility pools, view available shifts, and communicate directly with hiring managers. The platform caters to both short-term and long-term employment needs, promoting flexibility in work arrangements. By leveraging technology and artificial intelligence, Matchwell aims to enhance workforce management for healthcare organizations while providing transparency and direct access to job opportunities for clinicians. With over 50,000 clinicians and 1,000 healthcare sites under contract, Matchwell is actively redefining the dynamics of a flexible healthcare workforce.
WelbeHealth
Series C in 2020
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
Excision BioTherapeutics
Venture Round in 2019
Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.
SQZ Biotech
Series D in 2019
SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.
miRecule
Venture Round in 2019
miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.
She's Well
Seed Round in 2019
She’s Well brings a Netflix-like subscription model to fertility, to help women, men, and couples to have children when they’re ready. The company works with its network of top-tier fertility centers to provide financing plans for fertility testing, IVF, egg freezing and sperm freezing. With an on-demand concierge care approach, She’s Well provides support and guidance, to make the fertility journey less confusing and isolating. 1 in 6 couples has trouble conceiving and we’re waiting longer to try. Women increasingly delay childbirth - one in three women in the U.S. has her first child after 30 and one in ten after 35. Male sperm count has decreased over 50 percent in the last decade. Despite all the solutions available on the market, infertility services remain available to only 1%. Health plans usually don't cover infertility treatments. The typical costs range from 12,000 to 20,000 dollars for IVF, plus another few thousand for the genetic testing involved to ensure the fetus is chromosomally normal. To help, She’s well started out offering subscription plans and concierge guidance to make fertility care more affordable and accessible to the 99%. We need to usher a world where decisions about family and career aren't ruled by biological clocks and where the best options, science, and care are available to everyone who wants to start a family.
Meditrina
Venture Round in 2019
Meditrina, Inc. is a medical device company based in San Jose, California, specializing in tissue removal solutions for intrauterine pathology. Founded in 2016, the company has developed the Aveta System, an all-in-one solution designed for hysteroscopic diagnostic and therapeutic procedures. This system enables healthcare professionals to perform tasks such as the removal of polyps and fibroids in both office and operating room settings. The Aveta System features wide-angle HD hysteroscopy with electronic image-lock, advanced fluid management for better pressure and fluid control, and a compact design that allows for seamless integration into various medical environments. By providing advanced, convenient, and cost-effective options, Meditrina aims to enhance the care experience for both patients and physicians.
Luma Health
Series B in 2019
Luma Health Inc. is a San Francisco-based company that specializes in developing a patient engagement platform aimed at enhancing the connection between healthcare providers and patients. Founded in 2015, the platform facilitates smart scheduling and referral management while offering features such as appointment reminders, mobile patient intake, and care pathways. It enables healthcare systems and clinics to keep their schedules full and supports patient adherence to care plans. Additionally, Luma Health provides tools for patient communication and analytics, ensuring that healthcare providers can deliver continuous care and improve treatment outcomes. The company emphasizes a modern, mobile-first approach to patient engagement.
E25Bio
Seed Round in 2019
E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing rapid diagnostic tests for epidemic fever viruses, including dengue, chikungunya, and Zika. Founded in 2018, the company specializes in paper-based diagnostic systems that enable swift detection of viral antigens produced during infections. Its innovative platform allows for real-time data reporting through a mobile application, which captures results along with information on test timing and location. This approach aims to facilitate epidemiologic predictions and disease mapping, ultimately assisting governments and health organizations in managing outbreaks effectively and preventing public health crises. E25Bio's solutions are designed to provide affordable and timely diagnostics at the point of care.
Brave Care
Seed Round in 2019
Brave Care, Inc. specializes in urgent pediatric health care services, treating a wide range of conditions, including allergies, asthma, cough, ear pain, eye issues, fever, minor fractures, and rashes. The company also offers pediatric-specific laboratory services, on-site x-ray, and light sedation for certain procedures. Founded in 2019 and based in Portland, Oregon, Brave Care operates clinics exclusively designed for children in Oregon and Texas. In addition to in-person care, the BraveCare.com website and mobile app provide nationwide pediatric advice to assist parents in supporting their children's health and development.
Nurx
Series C in 2019
Nurx Inc. is a digital healthcare company that operates a mobile health platform, providing access to a variety of everyday medications, including contraceptives, travel medications, and prescriptions for conditions such as migraines and dermatological issues. Founded in 2015 and based in San Francisco, Nurx offers services that include doctor prescription reviews and at-home testing, such as Home HPV Screening for cervical cancer risk assessment. By allowing users to request medications and manage refills without the need for in-person visits, Nurx aims to empower individuals, particularly women, to take control of their health in a transparent and judgment-free environment. The company serves residents across multiple states, ensuring convenient and affordable healthcare solutions tailored to their needs.
Parachute Health
Venture Round in 2019
Parachute Health, LLC is a healthcare technology company based in New York, founded in 2015, that specializes in a platform designed for the ordering of durable medical equipment. This platform integrates with electronic medical record systems to streamline the process of prescribing medical equipment, offering features such as electronic messaging, real-time order status updates, and order history logs. By notifying clinicians about patients' insurance qualifications for equipment, Parachute Health enhances the efficiency of healthcare operations. The platform aims to reduce errors and improve the delivery time of medical supplies for discharged patients, ultimately enhancing patient care through better coordination and transparency in the healthcare supply chain. It serves healthcare facilities, providers, and suppliers, facilitating improved digital connectivity within the medical equipment procurement process.
Mahmee
Seed Round in 2019
Mahmee is an integrated care delivery platform focused on improving maternal and infant health. The company aims to address the critical gaps in the U.S. healthcare system, which faces high maternity costs and mortality rates, particularly among Black mothers and infants. By building a digital infrastructure that connects patients, independent health professionals, and healthcare organizations, Mahmee enhances access to comprehensive prenatal and postpartum care. Its platform includes a care management system that links health records for mothers and babies, flags clinical risks, and facilitates collaboration among maternity and infant care practitioners. Additionally, Mahmee’s marketplace allows new and expecting parents to discover care providers and access services both in-person and virtually, thereby supporting better health outcomes for families.
Legacy
Seed Round in 2019
Legacy provides a service for at-home sperm testing and cryopreservation, allowing individuals to take control of their fertility health from the comfort of their homes. Their semen analysis is conducted in CLIA-certified labs, ensuring high-quality testing without the need for direct doctor involvement. As America's largest at-home fertility clinic for men, Legacy empowers clients to understand their reproductive health and plan for the future effectively.
AdaptX
Venture Round in 2019
AdaptX is a healthcare data analytics and AI company that specializes in enhancing clinical and workflow outcomes for hospitals and surgery centers. Founded in Seattle in 2016 as a spin-off from Seattle Children's Hospital, AdaptX provides a platform that enables medical leaders and clinicians to access and analyze clinical data effectively. The platform integrates algorithms with existing electronic data systems, allowing healthcare providers to monitor performance, compare treatment approaches, and define patient cohorts. Through automated analytics, AdaptX helps healthcare service providers improve the quality and safety of care while also reducing costs.
Kindbody
Series A in 2019
Kindbody is a fertility clinic network and family-building benefits provider that offers a comprehensive range of services aimed at supporting individuals and couples in their journey to parenthood. The company's offerings include fertility assessments, preservation, genetic testing, in vitro fertilization (IVF), as well as donor, surrogacy, and adoption services. Employers collaborate with Kindbody to provide their employees with essential financial, medical, and emotional support throughout the family-building process. Kindbody serves over 100 employers, impacting more than 2.4 million lives, while also delivering fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. The organization emphasizes improving access to holistic health and fertility services for women at affordable rates, utilizing modern technology to enhance the patient experience.
StemoniX
Series B in 2019
StemoniX Inc. is a biotechnology company specializing in stem cell technologies to enhance drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a platform that focuses on the 3-D printing of stem-cell derived human tissues. This innovative approach allows for the creation of custom drug discovery models and facilitates the development of living cells in larger formats, addressing various medical conditions such as heart disease, dementia, breast cancer, autism, and ALS. The company's platform also operationalizes human induced pluripotent stem cell (iPSC) disease models for high-throughput screening, improving the research process for neurotoxicity and other drug screening efforts.
NeuSpera Medical
Series B in 2019
NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.
PharmaCCX
Seed Round in 2018
PharmaCCX, Inc. is a company that operates a market access platform designed to streamline the pricing and procurement of medicines for healthcare payers, thereby facilitating quicker patient access to necessary treatments. The platform primarily supports oncology pharmaceutical companies and various healthcare systems in the United States and Europe. Founded in 2017 and headquartered in Boston, Massachusetts, PharmaCCX also maintains offices in Stockholm, Sweden; San Mateo, California; and Zug, Switzerland. The company's software enhances the efficiency of market access teams within pharmaceutical companies and payers, enabling them to effectively plan, negotiate, and manage innovative payment models.
Mitra Biotech
Series C in 2018
Mitra Biotech is a biotechnology company that specializes in providing personalized cancer treatment. It aims on developing new technologies that surpass existing biomarker-guided strategies for cancer treatment selection, expanding access to truly personalized medicine, and enhancing the clinical management of cancer. The company was founded in 2010 and headquartered in Woburn, Massachusetts.
Apprentice Health
Seed Round in 2018
Apprentice Health is a predictive analytics firm focused on enhancing the efficiency of healthcare systems through its comprehensive operations platform. Based in Boston, Massachusetts, the company aims to facilitate the transition to value-based care by identifying inefficiencies in workflows within clinics and hospitals. Its platform provides actionable recommendations for improving scheduling, staffing, and facility utilization. By addressing these areas, Apprentice Health helps healthcare providers increase patient access, enhance the patient experience, and alleviate clinical staff burnout. The firm was founded by Rajiv Sivendran and Artur Menzeleev, emphasizing a commitment to higher patient and staff satisfaction while also reducing operational costs.
Vital Plan
Venture Round in 2018
Vital Plan provides supplements and lifestyle advice for individuals to live healthier and happier. Vital Plan brings transparency and credibility to the billions of natural products industry that is known for deceptive labeling, false claims, and low-quality ingredients, by providing guided educational wellness courses, health coaching, and physician-formulated supplement protocols. Vital Plan was founded on 2008 and is headquartered in Raleigh, North Carolina.
HealthMyne
Series B in 2018
HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative imaging solutions and analytics primarily for cancer care providers. The company's technology enhances clinical decision-making by offering real-time, evidence-based imaging insights that facilitate improved patient care while also reducing delivery costs. HealthMyne's platform includes features such as tumor image manipulation, automatic tumor staging, specialized reporting, and management of incidental findings, all aimed at streamlining clinical workflows. By integrating electronic health records and image repositories, HealthMyne supports physicians in diagnosing and treating patients more effectively, ultimately enhancing clinical collaboration and quality assurance in patient management.
Lumiata
Series B in 2018
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
WelbeHealth
Series B in 2018
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
Heal
Series C in 2018
Heal is a healthcare provider focused on delivering value-based, in-home primary care primarily to seniors on Medicare and select Medicare Advantage plans. The company emphasizes the importance of patient comfort by offering services in the familiar environment of patients' homes. Board-certified doctors and nurse practitioners at Heal dedicate ample time to each patient, fostering strong relationships and ensuring thorough, unrushed care. Heal addresses a wide range of healthcare needs, from preventive services like flu shots and annual physicals to the management of chronic conditions and treatment of common illnesses. Additionally, the company provides telemedicine options and remote health monitoring, facilitating easy access to care when needed. Patients can schedule appointments conveniently through phone support, with availability seven days a week, including weekends and holidays.
RubiconMD
Series B in 2018
RubiconMD, Inc. operates an online platform that facilitates communication between primary care clinicians and specialists through its eConsult service. This platform allows primary care providers to seek expert guidance on medical cases, thereby enhancing patient care and reducing healthcare costs. In addition to the eConsult service, RubiconMD offers a continuing medical education (CME) program for eConsult submissions, live and on-demand webinars, and RubiconRx, a clinical pharmacy platform that supports patient medication access. The company also provides support in electronic health records, workflow integration, onboarding, and clinician engagement. Founded in 2013 and headquartered in New York, RubiconMD serves a diverse clientele, including employers, community health centers, correctional health facilities, health plans, and direct primary care practices.
SHINE Technologies
Series B in 2018
SHINE Technologies specializes in the production of medical isotopes and the development of fusion technology. Its proprietary processes create essential isotopes such as molybdenum-99 and non-carrier-added lutetium-177, which are vital for diagnosing and treating serious health conditions, including heart disease and various forms of cancer. SHINE serves multiple sectors, including healthcare, aerospace, defense, and energy, providing safe and environmentally friendly solutions for industrial inspections and medical applications. The company is also focused on advancing its fusion technology to address energy challenges, including the recycling of nuclear waste. Through a phased and purpose-driven approach, SHINE aims to generate clean, abundant fusion energy, contributing to a healthier and more sustainable future.
New Aera
Venture Round in 2018
New Aera, Inc. is a medical device company based in San Ramon, California, founded in 2011. It specializes in developing, manufacturing, and marketing products aimed at individuals suffering from acute respiratory conditions. One of its key offerings is the SideKick TAV, a tidal assist ventilator designed for compatibility with various oxygen sources, including concentrators and cylinders. The company's products focus on enhancing respiratory therapy to alleviate breathlessness and improve exercise endurance, ultimately supporting cardiac patients in achieving better fitness and health. As of August 2019, New Aera operates as a subsidiary of Inogen, Inc.
American Gene Technologies
Series D in 2018
American Gene Technologies (AGT) specializes in developing innovative gene therapies aimed at curing serious diseases, including infectious diseases, cancers, and inherited disorders. The company is advancing its proprietary gene-delivery platform, which is backed by multiple patents, including those for its AGT103-T cell product designed to functionally cure HIV. AGT is also focused on a unique immuno-oncology approach that stimulates gamma-delta T cells to target various solid tumors. Additionally, the company has developed a synthetic gene to provide effective treatments for Phenylketonuria (PKU). AGT’s clinical trial for an HIV cure has the potential to not only address a significant public health challenge but also validate its technology platform for treating a variety of diseases.
DOTS
Venture Round in 2018
DOTS (Detection On The Spot) is changing the field of point of care detection with a revolutionary diagnostics platform with consumer and industrial applications. For the millions of consumers with food allergies, DOTS is creating a food allergen detection system to test food on the spot, provide more information for better decisions, and improve overall quality of life .
Siris Medical
Venture Round in 2018
Siris Medical, Inc. is a technology company based in Redwood City, California, that specializes in artificial intelligence-driven decision support systems for radiation therapy in cancer treatment. Founded in 2013, the company has developed the InsightRT Software Suite, which includes tools such as QuickMatch and PlanMD, designed to assist clinicians in managing patient treatment plans effectively. This platform is notable for being the first artificial intelligence decision support system in radiation oncology to receive FDA 510(k) clearance. It employs machine learning to provide real-time insights into treatment plan outcomes, helping clinicians make informed decisions regarding dosage, prescription, and treatment modalities, ultimately aiming to minimize side effects and expedite the initiation of patient treatment. Siris Medical is also affiliated with various innovation incubators, including North Shore InnoVentures and the UCSF / QB3 Rosenman program.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.